- Home
- KBDC vs VIR Comparison
KBDC vs VIR Comparison
Compare KBDC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- VIR
- Stock Information
- Founded
- KBDC 2021
- VIR 2016
- Country
- KBDC United States
- VIR United States
- Employees
- KBDC N/A
- VIR N/A
- Industry
- KBDC
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- KBDC
- VIR Health Care
- Exchange
- KBDC Nasdaq
- VIR Nasdaq
- Market Cap
- KBDC 1.1B
- VIR 1.0B
- IPO Year
- KBDC N/A
- VIR 2019
- Fundamental
- Price
- KBDC $16.62
- VIR $8.01
- Analyst Decision
- KBDC Buy
- VIR Buy
- Analyst Count
- KBDC 5
- VIR 5
- Target Price
- KBDC $17.10
- VIR $36.40
- AVG Volume (30 Days)
- KBDC 31.7K
- VIR 1.4M
- Earning Date
- KBDC 11-13-2024
- VIR 10-31-2024
- Dividend Yield
- KBDC 2.40%
- VIR N/A
- EPS Growth
- KBDC N/A
- VIR N/A
- EPS
- KBDC N/A
- VIR N/A
- Revenue
- KBDC N/A
- VIR $78,618,000.00
- Revenue This Year
- KBDC $164.31
- VIR N/A
- Revenue Next Year
- KBDC $16.04
- VIR N/A
- P/E Ratio
- KBDC N/A
- VIR N/A
- Revenue Growth
- KBDC N/A
- VIR N/A
- 52 Week Low
- KBDC $15.69
- VIR $7.12
- 52 Week High
- KBDC $16.80
- VIR $13.09
- Technical
- Relative Strength Index (RSI)
- KBDC N/A
- VIR 43.74
- Support Level
- KBDC N/A
- VIR $9.48
- Resistance Level
- KBDC N/A
- VIR $10.13
- Average True Range (ATR)
- KBDC 0.00
- VIR 0.64
- MACD
- KBDC 0.00
- VIR -0.07
- Stochastic Oscillator
- KBDC 0.00
- VIR 26.81
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.